Adjuvant nivolumab improves disease-free survival in patients with muscle invasive bladder cancer
Treatment with the PD1 inhibitor nivolumab with or without cisplatin-based chemotherapy after radical surgery significantly improve disease-free survival in patients with muscle-invasive urothelial cancer, regardless of PD-L1 status.
Få tilgang
Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.
- Få tilgang
- Hvis du allerede har en profil: Logg in
